Aclaris Therapeutics (ACRS) Cash from Operations (2014 - 2026)

Aclaris Therapeutics' Cash from Operations history runs 13 years deep, the most recent figure standing at 18149000.0 for Q1 2026.

• In Q1 2026, Cash from Operations fell 39.0% year-over-year to 18149000.0; the TTM figure through Mar 2026 stood at 52205000.0 (down 323.85% YoY), while the FY2025 annual figure was 47113000.0, down 134.68% from the prior year.
• Cash from Operations was 18149000.0 for Q1 2026 at Aclaris Therapeutics, down from 13131000.0 in the prior quarter.
• In the past five years, Cash from Operations ranged from a high of 22000000.0 in Q3 2024 to a low of 26353000.0 in Q1 2023.
• Historically, Cash from Operations has averaged 13601705.88 across 5 years, with a median of 13131000.0 in 2025.
• The sharpest annual moves came in 2023 and 2024: Cash from Operations plunged 214.15% in 2023, then jumped 189.59% in 2024.
• A 5-year view of Cash from Operations shows it stood at 19115000.0 in 2022, then surged by 64.63% to 6761000.0 in 2023, then plunged by 32.2% to 8938000.0 in 2024, then plunged by 46.91% to 13131000.0 in 2025, then sank by 38.21% to 18149000.0 in 2026.
• The last three Cash from Operations figures came in at 18149000.0 (Q1 2026), 13131000.0 (Q4 2025), and 10932000.0 (Q3 2025), per Business Quant data.